Rigontec, which develops RNA-based immunotherapeutics for the treatment of cancer, has raised $11.9m in a series A round featuring High-Tech Gruenderfonds.
Germany-based biopharmaceutical company Rigontec has raised €9.5m ($11.9m) in series A funding from investors including High-Tech Gruenderfonds, the German state-operated venture capital fund backed by several corporates.
Development bank NRW.Bank, venture capital firm Wellington Partners and venture fund Boehringer Ingelheim Venture Fund were also involved in the round.
Rigontec is developing treatments for cancer and viral diseases. The company was launched in January as a spin-out from University of Bonn’s Institute for Clinical Chemistry and Clinical Pharmacology.
Annegret de Baey-Diepolder,…
